Bernard Vanhove served as Research Director at the « Centre National de Recherche Scientifique » (CNRS, French National Scientific Research Institute), the « Institut National de la Santé et Recherche Médicale » (INSERM, National Institute for Health and Medical Research) and the « Centre Européen des Sciences de la Transplantation et Immunothérapie » (CESTI, European Center for Transplantation and Immunotherapy Sciences).
In 2013, Bernard Vanhove was awarded a Prize from « France Transplant » for his pharmacological preclinical studies evaluating the efficacy of FR104 (a pegylated monovalent anti-CD28 Fab antibody) in immunology. Moreover, he was the coordinator of the European FP7 network « TRIAD » (Tolerance Restoration in Autoimmune Diseases) in autoimmune diseases. He is the author of more than 90 international publications in the area of immune restoration.
In 2008, Bernard Vanhove co-founded Effimune, becoming Chief Executive Officer in July 2014. Upon the merger of Effimune with OSE Pharma in May 2016, he was appointed Chief Operating Officer of OSE Immunotherapeutics, in charge of R&D and International Scientific Collaborations.
Bernard Vanhove holds a Ph.D. in Immunology (from the Louvain University, Belgium).